Leadership Overview
Alexion has 5 executives leading key functions including strategy, financial oversight, marketing operations, regulatory development, and corporate leadership.
Dedicated to transforming lives through rare disease research, Alexion advances medical science by delivering innovative therapies for patients facing severe, life-threatening disorders across global markets.
Dedicated to transforming lives through rare disease research, Alexion advances medical science by delivering innovative therapies for patients facing severe, life-threatening disorders across global markets.
Leadership Roles at Alexion
Marc Dunoyer - Chief Executive Officer
Marc Dunoyer, the Chief Executive Officer at Alexion, directs the overarching strategic vision for the discovery and commercialization of life-saving biopharmaceuticals. Overseeing the entire organizational structure, the Chief Executive Officer ensures alignment between research initiatives and patient needs for rare disorders. This leadership role involves managing complex global operations while maintaining a focus on long-term growth and scientific excellence. By fostering collaboration across international research hubs, Marc Dunoyer drives the development of innovative therapies that address critical unmet medical needs. Dunoyer maintains rigorous standards for operational efficiency, ensuring the company remains at the forefront of the pharmaceutical industry. Through consistent engagement with the Board and executive leadership, the Chief Executive Officer secures the resources necessary to expand the reach of rare disease treatments, ultimately strengthening the market position of the organization within the competitive global healthcare landscape.
Sean Christie - Chief Financial Officer
Sean Christie, the Chief Financial Officer at Alexion, manages the fiscal health and capital allocation strategies required to support high-stakes biopharmaceutical development. Overseeing global financial planning, the Chief Financial Officer ensures that investment in rare disease research remains sustainable and aligned with long-term corporate objectives. This role involves navigating complex regulatory environments and optimizing resource distribution across international markets to maximize therapeutic impact. By implementing robust financial controls, Sean Christie supports the scaling of manufacturing capabilities and the expansion of commercial operations. Christie maintains transparency with stakeholders while driving initiatives that improve operational margins and fund critical clinical trials. Through precise financial modeling and risk assessment, the Chief Financial Officer provides the stability needed for the organization to pursue breakthrough medical discoveries, ensuring that capital flows efficiently toward the most promising life-threatening disorder treatments.
Patrice Coissac - President
Patrice Coissac, the President at Alexion, directs the execution of corporate strategy and oversees the daily operations of the biopharmaceutical business. Overseeing the alignment of departmental goals with the mission of treating rare disorders, the President ensures that the organization maintains a high standard of excellence in both research and commercialization. This role involves managing relationships with key partners and ensuring that the company remains agile in a rapidly evolving global market. By fostering a culture of innovation and accountability, Patrice Coissac drives the successful implementation of strategic initiatives across all business units. Coissac coordinates with other executive leaders to optimize the development pipeline and ensure that life-threatening disorder treatments reach patients efficiently. Through consistent leadership and operational oversight, the President maintains the competitive edge of the company, ensuring that the organization continues to deliver significant value to patients and stakeholders alike through its specialized pharmaceutical portfolio.
Moh-Lim Ong - Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Moh-Lim Ong, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer at Alexion, architects the commercial strategy and operational framework for bringing rare disease medicines to patients. Overseeing the integration of medical office functions with marketing outreach, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer ensures that clinical value propositions reach healthcare providers effectively. This role involves analyzing market data to identify gaps in treatment access and designing programs that accelerate the adoption of life-saving therapies. By aligning business planning with medical insights, Moh-Lim Ong drives the expansion of the company footprint across diverse geographic regions. Ong coordinates cross-functional teams to streamline the delivery of complex pharmaceutical products, ensuring that marketing efforts remain grounded in scientific evidence. Through strategic market positioning, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer enhances the visibility and accessibility of specialized treatments.
Mackenzie Halter - Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development
Mackenzie Halter, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development at Alexion, executes the operational strategy for regulatory compliance and safety protocols within the development pipeline. Overseeing the coordination between safety teams and development leadership, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development ensures that all clinical processes meet stringent global standards. This role involves managing the flow of critical data to regulatory bodies, facilitating the rapid approval of new therapies for rare disorders. By streamlining internal communication and project management, Mackenzie Halter drives efficiency across the entire development lifecycle. Halter supports the Head of Development in aligning safety initiatives with broader corporate goals, ensuring that patient welfare remains the primary focus during the drug approval process. Through meticulous oversight of regulatory milestones, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development secures the path for innovation.
Explore Leadership Teams in Manufacturing
Cadila Pharmaceuticals is one of India's largest private pharmaceutical companies, known for pioneering drug innovations across over 100 countries. The company focuses on making health simpler and safer through innovation-led drug discovery and R&D, offering over 850 products across 45 therapies and 12 specialties. Their services include formulation development, contract manufacturing, and clinical research, catering to a diverse range of therapeutic areas such as oncology, cardiology, and pediatrics. Cadila Pharmaceuticals is committed to providing affordable and accessible healthcare solutions while promoting sustainability and community well-being.
Company Leadership SG
DP
Moderna is recognized as a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered. By blending scientific innovation with advanced technology, the company continues to transform how society prevents and addresses disease across infectious conditions, cancer, rare disorders and autoimmune challenges. Guided by a distinctive culture and a global team committed to improving human health, Moderna focuses on developing mRNA-based medicines that can make a meaningful and lasting impact.
Company Leadership SI
JJ
Servier is an independent international pharmaceutical laboratory committed to therapeutic progress for the benefit of patients. The company focuses on three main therapeutic areas: oncology, cardio-metabolism, and neurology, aiming to address significant medical needs. Servier engages in research and innovation, collaborating with various partners to develop targeted therapies and improve patient care. Their long-term vision emphasizes sustainability and ethical practices in healthcare.
Company Leadership DM
KP
21st Century Vitamins operates as a globally recognized manufacturer and distributor of dietary supplements, positioned within the broader health and wellness industry. The company, through its parent entity 21st Century HealthCare, Inc., focuses on developing, producing, and delivering a wide range of vitamins, minerals, herbal supplements, and specialty nutritional products designed to support everyday health and well-being. With a history spanning more than three decades, the organization has established itself as a trusted and accessible brand in the consumer healthcare market. At its core, the company functions as both a manufacturer and a direct-to-consumer wellness provider. It produces an extensive portfolio of dietary supplements that cater to diverse health needs, including general nutrition, immune support, cardiovascular health, digestive wellness, sports nutrition, and beauty supplements. Its offerings range from traditional multivitamins and single-nutrient formulations to advanced blends such as amino acids, probiotics, and plant-based supplements. This breadth of product categories reflects the companys strategy of addressing a wide spectrum of consumer health requirements through scientifically formulated solutions.
Company Leadership SS
FC
KW
Frequently Asked Questions Regarding Alexion Top Executives and Leadership Team
